Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.85 |
| ▸ | HPGD | P15428 | 3/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.85 |
| ▸ | MEN1 | O00255 | 2/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.85 |
| ▸ | MTOR | P42345 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | KDM1A | O60341 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010737 | 1.00 | TRPV1 (0.85) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL1286875 | 1.00 | TRPV1 (0.85) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL27205211 | 0.99 | TRPV1 (0.88) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL1586354 | 0.99 | TRPV1 (0.88) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL8154574 | 0.97 | TRPV1 (0.84) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL10407917 | 0.97 | TRPV1 (0.84) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL10543855 | 0.97 | TRPV1 (0.84) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL12313044 | 0.93 | TRPV1 (0.89) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| Olvanil SCHEMBL537603 | 0.92 | TRPV1 (1.00) | TRPV1CYP1A2CYP3A4MAPTHPGD | |
| SCHEMBL10711239 | 0.92 | TRPV1 (0.96) | TRPV1CYP1A2CYP3A4MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10821088-B2 | Pain relief compositions, manufacture and uses | PROPELLA THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3316856-A1 | BLENDED FORMULATIONS | Sequessome Technology Holdings Limited (MT) | 2018-05-09 | — | — | EP | disclosed |
| EP-3316857-A1 | MULTIPHASIC COMPOSITIONS | Sequessome Technology Holdings Limited (MT) | 2018-05-09 | — | — | EP | disclosed |
| US-20170362162-A1 | SYNTHESIS OF AMIDES AND AMINES FROM ALDEHYDES OR KETONES BY HETEROGENEOUS METAL CATALYSIS | ORGANOFUEL SWEDEN AB (SE) | 2017-12-21 | — | — | US | disclosed |
| US-20170362162-A1 | SYNTHESIS OF AMIDES AND AMINES FROM ALDEHYDES OR KETONES BY HETEROGENEOUS METAL CATALYSIS | ORGANOFUEL SWEDEN AB (SE) | 2017-12-21 | — | — | US | disclosed |
| WO-2017001617-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2017-01-05 | — | — | WO | disclosed |
| WO-2017001625-A1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2017-01-05 | — | — | WO | disclosed |
| US-20160106690-A1 | PAIN RELIEF COMPOSITIONS, MANUFACTURE AND USES | API GENESIS, LLC (US) | 2016-04-21 | — | — | US | disclosed |
| US-8889659-B2 | Pain relief compositions, manufacture and uses | API GENESIS, LLC (US) | 2014-11-18 | — | — | US | disclosed |
| WO-2014159884-A1 | APPLICATION OF ENCAPSULATED CAPSAICIN AND ANALOGUES THEREOF FOR CONTROLLING CALORIE INTAKE | Altria Client Services Inc. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2011138565-A1 | PHARMACEUTICAL COMBINATION CONTAINING LIPOIC ACID, HYDROXYCITRIC ACID AND A SOMATOSTATIN AS ACTIVE INGREDIENTS | BIOREBUS (FR) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10821088-B2 | Pain relief compositions, manufacture and uses | TRPV1, OPRL1, TRPV3 | TRPV1 1/4885CYP1A2 2370/4885CYP3A4 3414/4885 |
| US-20160106690-A1 | PAIN RELIEF COMPOSITIONS, MANUFACTURE AND USES | TRPV1, OPRL1, TRPV3 | TRPV1 1/4885CYP1A2 2370/4885CYP3A4 3414/4885 |
| US-20170362162-A1 | SYNTHESIS OF AMIDES AND AMINES FROM ALDEHYDES OR KETONES BY HETEROGENEOUS METAL CATALYSIS | DCXR, ADH5, CBR1 | TRPV1 31/4885CYP1A2 1151/4885CYP3A4 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.